Anthem Blue Cross and Blue Shield and Eli Lilly and Company Establish Coalition
Anthem Blue Cross and Blue Shield and Eli Lilly and Company have joined with five other leading health organizations in Indiana to form the Healthy Hoosiers Alliance with a goal to fill the gaps in diabetes care by addressing health care quality, safety, access, and affordability.
March 27, 2009
NICHD/NIH to Conduct Clinical Study with Agile’s Contraceptive Patch
Agile Therapeutics, Inc. announced that it has signed a Clinical Trial Agreement with the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to evaluate Agile’s progestin-only contraceptive patch.
March 26, 2009
ZyGEM and VWR International Sign Distribution Agreement
ZyGEM Corp. Ltd. and VWR International, LLC announced that they have entered into an exclusive distribution agreement for ZyGEM’s innovative DNA extraction kits.
March 26, 2009
Roche Completes Tender Offer for Genentech
Roche announced that its wholly-owned subsidiary, Roche Investments USA Inc., completed its tender offer for the publicly held shares of Genentech.
March 26, 2009
ADVENTRX Grants Exclusive Rights to ANX-514 in South Korea
ADVENTRX Pharmaceuticals, Inc. announced that it has granted Shin Poong Pharmaceutical Co., Ltd. exclusive rights in South Korea to make, use and sell ANX-514 (docetaxel emulsion), one of its two lead product candidates.
March 25, 2009
Tekmira Pharmaceuticals Extends Research Collaboration with Bristol-Myers Squibb
Tekmira Pharmaceuticals Corporation announced that Bristol-Myers Squibb Company has exercised an option to extend through 2009 the research collaboration between the two companies.
March 25, 2009
Vyteris Announces Agreement for Additional Funding
Vyteris, Inc. announced that its development partner, Ferring Pharmaceuticals Inc., further deepened its commitment to Vyteris by agreeing to fund the first half of the 2009 development budget for its joint partnership with Vyteris in developing a pulsatile delivery of a peptide hormone for treatment of infertility in women.
March 25, 2009
Human Genome Sciences and Morphotek Announce Collaboration
Human Genome Sciences, Inc. and Morphotek, Inc. announced that they have entered into a collaboration to discover, develop, and commercialize therapeutic monoclonal antibodies in the fields of oncology and immunology that specifically target antigens discovered by HGS.
March 25, 2009
NovaBay and Galderma Enter into Global Agreement
NovaBay Pharmaceuticals, Inc. announced that it has entered into an agreement with Galderma S.A. to develop and commercialize NovaBay’s novel proprietary Aganocide compounds.
March 25, 2009
Genedata Collaborates with TcLand Expression
Genedata announced a collaboration with TcLand Expression where the Genedata Phylosopher and Expressionist biomarker discovery platforms will be integrated into TcLand Expression’s computational infrastructure.
March 24, 2009
Biovitrum AB Signs Collaboration Agreement with Affibody AB
Biovitrum AB signed a collaboration agreement with Affibody AB with the aim of developing new targeted therapeutics for inflammation and autoimmune diseases.
March 24, 2009
Endo Pharmaceuticals Completes Acquisition of Indevus Pharmaceuticals
Endo Pharmaceuticals announced the successful completion of its acquisition of Indevus Pharmaceuticals, Inc.
March 23, 2009
China Biologic Products Completes Acquisition of Xi’an Huitian Blood Products
China Biologic Products, Inc. announced that, its indirect majority owned subsidiary, Shandong Taibang Biological Products Co., Ltd., has completed the government approval process for the transfer of 35% of the equity interest in Xi’an Huitian Blood Products Co., Ltd.
March 23, 2009
Life Technologies and Nanosys Enter Into Quantum Dot Licensing Deal
Life Technologies Corporation and Nanosys, Inc. announced a cross-licensing agreement to share rights to an intellectual property estate related to fluorescent nanocrystals (also known as quantum dots).
March 23, 2009
MDRNA Signs Licensing Deal with Novartis
MDRNA, Inc. announced that it has entered into a licensing agreement with Novartis for MDRNA’s liposomal technology platform for siRNA delivery.
March 23, 2009
Advanced Proteome Therapeutics Works with Atreus Pharmaceuticals
Advanced Proteome Therapeutics Inc. working with Atreus Pharmaceuticals Corporation announced that its scientists have successfully site-specifically modified annexin V, a member of the annexin family of human plasma proteins using a proprietary chemical approach.
March 23, 2009
BioDuro and AstraZeneca Expand Collaboration
BioDuro and AstraZeneca announced that they have expanded their research collaboration to optimize discovery research for Respiratory and Inflammation indications.
March 23, 2009
Filed Under: Drug Discovery
